UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 17

of '进展期(晚期)或转移性肾透明细胞癌的抗血管生成和分子靶向治疗'

17
TI
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
AU
Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK
SO
N Engl J Med. 2014;370(18):1769.
 
AD
Memorial Sloan-Kettering Cancer Center, New York, NY motzerr@mskcc.org.
PMID